Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Presentation overview
3. ICH E15 definitions
4. Promise of genomics
5. The complexity in predicting therapy
6. What can the science do?
7. Pharmacogenomic data impact
8. Role of pharmacogenomics in patient outcomes
9. Impact report
10. Pharmacogenomics implementation barriers
11. Opportunity of personalized medicine
12. Falling costs of genomic technologies
13. IL28B and peginterferon-a-2b treatment in HCV
14. The research and development 'process'
15. No increased productivity with advance in science
16. Scientific challenges for pharma R&D
17. Increasing shots on goal has not worked
18. Reasons for phase 2 failures
19. Getting the right medicine to the right patients
20. Translational collaborations in drug discovery
21. Why future use samples are useful
22. Primary barriers to successful genetic research
23. Risk/benefit
24. Research scope
25. Broad consent for future biomedical research
26. Future vision
27. Privacy protection
28. Value proposition
29. Getting closer to individualized therapy
30. Identifiability of DNA

Topics Covered

• The promise of genomics
• The complexity in predicting therapy
• Pharmacogenomic data impact & implementation barriers
• Opportunity of personalized medicine
• Costs of genomic technologies and the research & development 'process'
• Scientific challenges for pharma R&D and primary barriers to successful genetic research
• Reasons for research failures
• Getting the right medicine to the right patients
• Translational collaborations in drug discovery
• Future biomedical research and vision while keeping privacy protection and value proposition in mind

Links

Series:

• Biomarkers

Categories:

• Genetics & Epigenetics
• Pharmaceutical Sciences

Talk Citation

Warner, A. (2012, December 27). Pharmacogenomics: emphasis on clinical drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 20, 2024, from https://hstalks.com/bs/2459/.
Export Citation (RIS)

Publication History

• Published on December 27, 2012

Financial Disclosures

• Dr. Amelia Warner, Stock Shareholder (Self-managed): Merck